Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to share their insight on managing care for cancer and learn about all the new treatment strategies that have been developed, are being developed, or need to be developed in the future.
This year’s meeting will feature more than 5000 abstracts, many of which are already available online, with topics ranging from how to best use the new line of immunotherapies that have recently hit the market for various disease types to ways of managing costs for certain patients with breast cancer.
------
Related Content
ASCO releases clinical pathways in oncology policy statement
ASCO’s Take on Clinical Pathways
------
The theme for ASCO 2016 is ‘Collective Wisdom: the future of patient-centered care and research,” which emphasizes partnerships and collaboration among different health care professionals and specialists of diverse backgrounds to meet the evolving challenges in providing optimal care to patients with cancer. In addition, advances in new technologies have provided never-before-seen potential for harnessing data across large patient groups in order to identify the best possible outcomes for each individual patient.
However, these advances are only as useful has health care professionals’ ability to understand and utilize them at the clinical level. At ASCO 2016, attendees will have the opportunity to hear about a number of new perspectives on important issues in care and exchange ideas and information with colleagues.
Journal of Clinical Pathways will be covering all the big sessions and abstracts related to clinical pathways, value-based care, and comparative-effectiveness research below. Check back for updates on these topics and other important presentations.
------
Venetoclax Response in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
In an ongoing clinical trial, investigators examined the effectiveness of venetoclax, a selective oral BCL-2 inhibitor, in patients relapsed or refractory to ibrutinib or idelalisib.
New Treatment Improves Response in ALK-Positive NSCLC
In a phase II clinical trial, investigators assessed how overall response rate changed when patients were treated with different doses of a tyrosine kinase inhibitor for resistant ALK mutations in non-small cell lung cancer.
Daratumumab More Cost Effective for Multiple Myeloma Treatment
To evaluate the cost-effectiveness of different therapeutic options available to certain patients with multiple myeloma, researchers developed a model to estimate the cost per median month of survival in patients treated with daratumumab, carfilzomib, and pomalidomide plus dexamethasone.
Significant Cost Variation in Breast Cancer Chemotherapy
Researchers conducted a study to generate estimates of costs associated with guideline-concordant breast cancer adjuvant chemotherapy regimens.
Non-Platinum-Based Chemotherapy May Worsen Survival in some Patients with Ovarian Cancer
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
Discontinuing Treatment With Nivolumab Does Not Affect Survival in Patients With Melanoma
In a trial enrolling 142 patients to receive nivolumab plus ipilimumab or a placebo plus ipilimumab, looked at how survival changed in patients who discontinued treatment due to toxicity.
Web Application Improves Survival and Follow-up for Patients With Lung Cancer
Using a web application developed by French researchers may help clinicans to better manage follow-up for patients with lung cancer and improve outcomes.
Prostate Cancer Treatment Associated With More Adverse Events
Researchers conducted a retrospective analysis to compare the occurrence of adverse events in patients treated with abiraterone acetate and prednisone or enzalutamide for prostate cancer.
Doctors discussed how the presentation of human epidermal growth factor receptor 2 and estrogen receptors can have an influence on treatment strategies and the effectiveness of certain targeted therapies.
ASCO/European CanCer Organisation (ECCO) Joint Session: Value-Based Care
In this joint session between the American Society of Clinical Oncology and the European CanCer Organisation, representatives from both groups discussed strategies for delivering more value-based care.
The addition of bevacizumab to neoadjuvant chemotherapy may improve the achievement of pathologic complete response without increasing incidence of toxicity in certain patients with breast cancer.
Quality of Life an Important Factor in Sarcoma Treatment
Understanding health-related quality of life (HRQoL) and the impact of disease progression may be critical factors for the long-term care and survival of patients with soft-tissue sarcoma (STS), according to a study presented at the 2016 meeting.
Biden announces U.S. project to promote cancer data sharing
U.S. Vice President Joe Biden said on Monday the "moonshot" initiative he leads aimed at finding cures for cancer was "the only bipartisan thing left in America" and called for more collaboration among researchers, doctors and government agencies to advance the cause.
Nivolumab Effective for Advanced Bladder Cancer
Clinical trial results have shown that patients with advanced bladder cancer may have their tumor burdens reduced through treatment with nivolumab.
Quality and Value: Measuring and Utilizing Both in Your Practice
In this session at the American Society of Clinical Oncology Annual Meeting, presenters discussed the benefits of measuring the quality of care though the Quality Oncology Practice Initiative and how ASCO's Value Framework is trying to transform care delivery.
Pembrolizumab Leads to Improved Survival in Patients With Melanoma
Investigators enrolled 655 patients with advanced melanoma in a clinical trial to assess the effectiveness of pembrolizumab treatment.
MACRA Town Hall: Effects on your Medicare Reimbursement
At the American Society of Clinical Oncology Annual Meeting, presenters provided insight and reccomendations on what will be the new reimbursement model under MACRA.
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
In an oral abstract session, researchers presented findings from a number of studies analyzing the effectiveness of different treatments for breast cancer.
Financial Toxicity: Risks, Outcomes, and Solutions
Late in the afternoon on Saturday, June 4, presenters explored possibly solutions and interventions to reduce financial toxicity, an increasingly burdensome issue among patients with cancer and a factor that can often lead to poorer overall health outcomes if it is not given proper attention.
Findings from a poster at the American Society of Clinical Oncology Annual Meeting show that hazard ratios for progression-free survival are a predictor of hazard ratios for overall survival and may therefore be a suitable surrogate for OS in trials evaluating second-line treatments and beyond.
Complex Decision-Making in Clinical Practice: Interpreting HER2 Results
In this session, David G Hicks, MD, University of Rochester and Javier Cortes, MD, PhD, Vall d’Hebron Institute of Oncology, aim to provide clinicians with a thorough overview of human epidermal growth factor receptor 2 (HER2)–positive breast cancer and the influence of the HER2 biomarker on clinical decision-making.
Practicing in the Age of Value-Based Clinical Pathways
In a landmark session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7; Chicago, IL), a variety of health care stakeholders will discuss how care has changed with the advent and dissemination of clinical pathways.
A Cost-Effectiveness Analysis of Palbociclib Plus Letrozole as First-Line Treatment for Estrogen Receptor-Positive, HER2-Negative, Metastatic Breast CancerA poster at the American Society of Clinical Oncology 2016 Annual Meeting (June 3-7, 2016) reports that palbociclib plus letrozole may be too expensive to be considered a cost-effective, first-line treatment option for patients with metastatic breast cancer.
Transplant Still Preferred Treatment Choice in Young Patients With Myeloma
Autologous stem cell transplantation is still the preferred treatment of choice for patients under the age of 65 years with newly diagnosed multiple myeloma, according to early results from a phase 3 trial presented during a press briefing ahead of ASCO 2016.
